The Latest: Nevada Supreme Court taking up execution case

FILE - This undated file photo provided by Nevada Department of Corrections photo shows death row inmate Scott Raymond Dozier, who was convicted in 2007 of robbing, killing and dismembering a 22-year-old man in Las Vegas, and was convicted in Arizona in 2005 of another murder and dismemberment near Phoenix. Dozier whose execution has twice been postponed says Wednesday, Aug. 8, 2018, the legal fight over his fate is taking a tortuous toll on him and his family and he just wants his sentence carried out. (Nevada Department of Corrections via AP, File)

FILE - This undated file photo provided by Nevada Department of Corrections photo shows death row inmate Scott Raymond Dozier, who was convicted in 2007 of robbing, killing and dismembering a 22-year-old man in Las Vegas, and was convicted in Arizona in 2005 of another murder and dismemberment near Phoenix. Dozier whose execution has twice been postponed says Wednesday, Aug. 8, 2018, the legal fight over his fate is taking a tortuous toll on him and his family and he just wants his sentence carried out. (Nevada Department of Corrections via AP, File)

LAS VEGAS — The Latest on court arguments about the drugs that would be used for Nevada to execute its first death-row inmate in 12 years (all times local):

10:10 a.m.

The Nevada Supreme Court has stepped in to decide whether drug companies can try to stop the state from using their medications in a twice-postponed lethal injection of a condemned inmate who wants to die.

A state court judge in Las Vegas cancelled hearings Thursday following an order late Wednesday from six of the high court’s seven justices.

Supreme Court intervention had been sought by the state attorney general’s office regarding the execution of Scott Raymond Dozier.

The judge had planned to hear drugmaker Sandoz’s request to join a bid by Alvogen and Hikma Pharmaceuticals to prevent Nevada from using their products in a three-drug combination never before tried in any state.


Comments

Use the comment form below to begin a discussion about this content.

Sign in to comment